

Electronic Acknowledgement Receipt

| | |
|---|---|
| EFS ID: | 4700257 |
| Application Number: | 10524963 |
| International Application Number: | |
| Confirmation Number: | 3567 |
| Title of Invention: | N-(3-Methoxy-5-methylpyrazin-2-yl)-2-(4'-1,3,4-oxadiazol-2-ylphenyl)pyridine-3- sulphonamide as an anticancer agent |
| First Named Inventor/Applicant Name: | David William Tonge |
| Customer Number: | 44992 |
| Filer: | Jacob G. Weintraub |
| Filer Authorized By: | |
| Attorney Docket Number: | 100815-1P US |
| Receipt Date: | 30-JAN-2009 |
| Filing Date: | 18-FEB-2005 |
| Time Stamp: | 23:11:33 |
| Application Type: | U.S. National Stage under 35 USC 371 |

Payment information:

| | |
|------------------------|----|
| Submitted with Payment | no |
|------------------------|----|

File Listing:

| Document Number | Document Description | File Name | File Size(Bytes)/ Message Digest | Multi Part /.zip | Pages (if appl.) |
|-----------------|----------------------|--------------------------------------|---|------------------|------------------|
| 1 | NPL Documents | 59RosanoAACR2008oralpresentation.PDF | 21306554 d6bed79121b6e6c7c2c26149948a31800000b0f64 | no | 15 |

Warnings:

Information:

| | | | | | |
|---------------------|---------------|--|--|----|----|
| 2 | NPL Documents | 60RosanoExpBiologyandMedicine200611321135231.PDF | 743778 596f6c02c1620549972a3aac2f4a3f31b59642 | no | 4 |
| Warnings: | | | | | |
| Information: | | | | | |
| 3 | NPL Documents | 61SmollichAACR2008absPR8.PDF | 143815 d40e3652f14b2956b4d4d481e4d74ef8bcb71e48 | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 4 | NPL Documents | 62Smollich2008AACRpresentation.PDF | 2261248 418c008517a9c1e06e4d21b59a003b1c0f8db6c34 | no | 10 |
| Warnings: | | | | | |
| Information: | | | | | |
| 5 | NPL Documents | 63Smollich2008Anticancerher2008148149389.PDF | 2370519 b0bce4f8b0edebd08e16a2cc5b71168281101 | no | 13 |
| Warnings: | | | | | |
| Information: | | | | | |
| 6 | NPL Documents | 64StenslanActaCryst2004o1817o1819610.PDF | 424513 d186e8a7cc5f108928112a5a5cc01019a8c28 | no | 3 |
| Warnings: | | | | | |
| Information: | | | | | |
| 7 | NPL Documents | 65Swaisland2007abstractP84.PDF | 115914 5f7d6db13b16c8b0a93d54505226c62187913f | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 8 | NPL Documents | 66Swaisland2007poster.PDF | 279334 40ca043424f327b098b124594936c290386c0bb | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 9 | NPL Documents | 67VenutiAscoAbstracts2001.PDF | 118631 c81e483e617ab535c518ad3e5423dc55f8ea5 | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 10 | NPL Documents | 68VerharBritClinPharm200056257349.PDF | 1910847 b4222d46aa09aac3b6c1e145e42a7fb43 | no | 12 |
| Warnings: | | | | | |
| Information: | | | | | |

| | | | | | |
|-------------------------------------|---------------|--|--|----|---|
| 11 | NPL Documents | 69WarrenExpOpinInvestDrugs200812371245178.PDF | 9209919 52581a0f9b6b97132613337d423f93e41c59008 | no | 9 |
| Warnings: | | | | | |
| Information: | | | | | |
| 12 | NPL Documents | 70WilliamsAACR2006poster.PDF | 592289 48732b65d8b7364c4549c9248b6c59b55854868 | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 13 | NPL Documents | 71WilliamsMoCancerTher2007612SuppllabsA271.PDF | 252763 6b54a680cb7f7181c5c2979b44862756c38c13edc4 | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 14 | NPL Documents | 72WilliamsEurJofCancerSupp200615412.PDF | 55011 96d8f1e3e904b27b703d803acde5d4147dfe8614 | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 15 | NPL Documents | 73WulfingMolCancerTher2007612suppllabsA275.PDF | 493712 a392376e48f5f957a3116f457a918a2182d906c | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 16 | NPL Documents | 74WulfingAACR2007poster.PDF | 601952 20d70b91471878d6d41d8b67002216f4eef8b657f | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 17 | NPL Documents | 75ZonnenbergCalcifTissueInt2008Supp1595AbsP093.PDF | 102429 3c9175372aa0f504c50b4d69d15dc077421bc37 | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 18 | NPL Documents | 76Zonnenberg2008poster.PDF | 500625 0cb1282d8624c005c0b1dc4a01cbb32299d41c | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| Total Files Size (in bytes): | | | 41483853 | | |

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.